Pfizer’s Outlier Quarter, At Both Extremes
Executive Summary
Investors are trying to wrap their minds around exactly how big Pfizer’s COVID vaccine business will end up being. But they also have questions about Pfizer’s prospects at the opposite end of the patient-population spectrum.